Bitcoin sets a new all-time high above $6,000 >>> READ MORE


Recent Articles

Gilead Sciences (GILD) Sales Growth Hampers Rating

Portfolio Grader currently ranks Gilead Sciences Inc (NASDAQ:GILD) a Hold. The methods for fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week. GILD has maintained this ranking for the last month. More 

It’s Time to Start Buying Beaten-Up Gilead Sciences, Inc. (GILD) Stock

Gilead has been sliding, but HCV market consolidation and potential exponential growth in the CAR-T market imply upside for GILD stock. More 

Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy

Gilead Sciences’ Kite pharma deal is a good move while the underlying business in Hepatitis and HIV grows in 2018. More 

Gilead Sciences (GILD) Raised to Hold from a Sell

Currently, Gilead Sciences Inc (NASDAQ:GILD) has a Hold using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing approach. GILD has been upgraded from a Sell to a Hold in the last week. More 

4 Biotech Stocks (and 1 ETF) to Buy As They Bolt Higher

These biotech stocks are making a comeback amid several positive catalysts for the sector and markets as a whole. More 

How Will Trump’s Proposed Tax Reform Impact Drug Companies?

Donald Trump has proposed new tax reforms for individuals and corporates. Let’s see how the reforms, if passed, will impact pharma companies. More 

Gilead Sciences, Inc. (GILD) Stock Got Its Mojo Back

For a while GILD stock was a hideous knife to catch. But now that it reestablished its bottom, I can safely make money in Gilead. More